Motexafin lutetium
| |
| Names | |
|---|---|
| Other names
Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChemCID
|
|
| UNII | |
| |
| Properties | |
| C52H72LuN5O14 | |
| Molar mass | 1166.136g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).
| |
Motexafin lutetiumis atexaphyrin,marketed asAntrinby Pharmacyclics Inc.
It is a photosensitiser for use inphotodynamic therapyto treat skin conditions and superficial cancers.
It has also been tested for use inphotoangioplasty(photodynamic treatment of diseased arteries).[1]
It is photoactivated by 732 nm light which allows greater depth of penetration.[2]
Clinical trials[edit]
Phase II clinical trials were in progress in 1999.[3]
A phase I trial forprostate cancerreported in 2009.[4]
References[edit]
- ^Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery DiseaseArchived2011-07-16 at theWayback Machine,2002
- ^http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
- ^Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCTArchived2012-07-13 atarchive.today,1999
- ^Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008)."Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA".Clinical Cancer Research.14(15): 4869–76.doi:10.1158/1078-0432.CCR-08-0317.PMC2680073.PMID18676760.
 | Thisdermatologicdrugarticle is astub.You can help Wikipedia byexpanding it. |